Climb Bio (CLYM) investor relations material

Strategic overview and pipeline focus

• Emphasis on execution in 2025, with foundational work enabling a rich data year in 2026 across both lead programs.

• Focus on B-cell mediated diseases using monoclonal antibodies, with budoprutug (CD19 mAb) as the lead asset and a newly in-licensed APRIL-only antibody (CLYM116).

• Differentiation from competitors by targeting broader B-cell populations and developing subcutaneous formulations for improved patient access.

• Initial indications target areas with high unmet need and limited competition, such as PMN, ITP, SLE, and IgAN.

• Synergies between programs in infrastructure and expertise, especially in renal and autoimmune indications.

Clinical development and upcoming data readouts

• Subcutaneous healthy volunteer data for budoprutug expected in the first half of 2026, aiming to demonstrate comparable B-cell depletion to IV dosing.

• Initial data from ITP, SLE, and PMN studies anticipated in the second half of 2026, focusing on early biomarkers, safety, and efficacy signals.

• PMN study targets moderate to severe patients, with early biomarker and proteinuria data expected, but not full 1-year endpoints.

• ITP study includes three dose cohorts (six patients each), focusing on treatment-refractory, third-line patients and platelet response as the primary endpoint.

• SLE study designed for translational biomarker assessment rather than clinical endpoints, exploring potential for durable remission or chronic therapy.

Competitive landscape and product differentiation

• CD19 targeting offers broader B-cell depletion than CD20, with clinical evidence supporting efficacy in diseases where CD20 therapies have failed.

• Subcutaneous formulation of budoprutug may unlock new indications and improve patient convenience.

• CLYM116 (APRIL-only antibody) features a sweeper mechanism, half-life extension, and potentially lower immunogenicity compared to competitors.

• Head-to-head non-human primate data showed superior half-life and IgA suppression versus sibeprenlimab.

• Market for IgAN expected to evolve rapidly, with APRIL-only therapies potentially preferred due to safety and efficacy profile.